Promising first‐line immuno‐combination therapies for unresectable hepatocellular carcinoma: A cost‐effectiveness analysis
As one of the promising immuno-combination therapies in the first-line systemic treatment of HCC, camrelizumab plus rivoceranib demonstrated the potential to be the most cost-effective strategy, which warranted further studies to best inform the real-world clinical practices.
Authors
- Qiuji Wu (ORCID: https://orcid.org/0000-0001-9205-4193)
- Qiu Li (ORCID: https://orcid.org/0000-0002-5299-9050)
- Yang Yang (ORCID: https://orcid.org/0000-0001-9743-841X)
- Mengxi Zhang (ORCID: https://orcid.org/0000-0003-4380-794X)
- Kexun Zhou (ORCID: https://orcid.org/0000-0001-8664-3581)
- Peng Huang (ORCID: https://orcid.org/0000-0003-4102-946X)
- Feng Wen (ORCID: https://orcid.org/0000-0003-0642-0164)
Institutions
- Sichuan University (CN)
- Sichuan Cancer Hospital (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1002/cam4.70094
- Citations
- 8
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.26
Funders
- Department of Science and Technology of Sichuan Province
- Sichuan University